RecruitingNot ApplicableNCT05980052

Goal Setting to Promote Physical Activity Adherence in Midlife Adults

Goal Setting to Promote Physical Activity Adherence in Midlife to Reduce Risk of Alzheimer's Disease and Related-Dementias: A Randomized Mechanistic Proof-Of-Concept Trial

Sponsor

Arizona State University

Enrollment

144 participants

Start Date

Jul 17, 2023

Study Type

INTERVENTIONAL

Conditions

Exercise Physical Activity

Summary

Engaging in regular physical activity during midlife is a key lifestyle behavior associated with reduced risk for Alzheimer's disease and related dementias (AD/ADRD). Yet nearly half of midlife adults (48%) do not meet national physical activity guidelines. The purpose of this mechanistic trial is to identify effective goal setting techniques to enhance psychosocial processes of self-regulation for the successful promotion of PA and adherence to national PA guidelines among midlife adults, with the long-term goal of reducing AD/ADRD risk

Eligibility

Min Age: 45 YearsMax Age: 65 Years

Inclusion Criteria5

Aged 45 to 65 years
BMI between 30 kg/m2 to 50 kg/m2
Participants must weigh a minimum of 110 pounds
Engaging in 60 minutes or less of self-reported moderate-to-vigorous physical activity at screening (based on Exercise Vital Sign Questionnaire)
Self-reported ownership of a smartphone with an iOS or Android operating system (necessary for participants to track their activity using a Fitbit activity monitor)

Exclusion Criteria12

Endorsing an item on the Physical Activity Readiness Questionnaire (PAR-Q), unless a physician's note is provided
Resting blood pressure greater than 200/110 mmHG as assessed at the baseline study assessment (unless a physician's note is provided)
Pregnant or planning to become pregnant in next 8-months (Phase 1) or 12 months (Phase 2)
Plans to relocate out of metropolitan Phoenix, Arizona area in the next 8-months (Phase 1) or 12 months (Phase 2)
Participation in another physical activity, nutrition or weight loss program at time of screening or at any time during the intervention
Individuals with mild cognitive impairment (MCI), as determined by either a self-report of receiving a diagnosis of MCI from a health care provider or as assessed by the Montreal Cognitive Assessment (MoCA) at the study orientation session. A score \< 26 is an exclusion criterion for US born participants. A score of \<23 is an exclusion for participants born outside of the US who completed their high school education in a country where English is not the primary language.
Being previously prescribed one of the 5 approved Alzheimer's medications, including: Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Razadyne), Memantine (Namenda), Memantine + Donepezil (Namzaric)
Score of 16 or higher on the Center for Epidemiological Studies-Depression Scale (CES-D)
Self-reported current diagnosis of major depression
Currently taking 2 or more ant-depression drugs
History of stroke
Incarcerated individuals (i.e., Prisoners)